Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$26.55 USD
-0.38 (-1.41%)
Updated Sep 24, 2024 04:00 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Company Summary
Myriad Genetics, headquartered in Salt Lake City, UT, employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company currently has 12 proprietary molecular diagnostic products in the market.
Currently, Myriad Genetics has so far made significant progress with its five strategic imperatives, which include transitioning and expanding the hereditary cancer market, diversifying revenues by commercializing its new products, increasing the company’s international contribution by investing in large ...
Company Summary
Myriad Genetics, headquartered in Salt Lake City, UT, employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company currently has 12 proprietary molecular diagnostic products in the market.
Currently, Myriad Genetics has so far made significant progress with its five strategic imperatives, which include transitioning and expanding the hereditary cancer market, diversifying revenues by commercializing its new products, increasing the company’s international contribution by investing in large countries, gaining reimbursement for new products, increasing international RNA kit revenue and enhancing profitability with Elevate 2020.
In November 2022, the company acquired Gateway Genomics, LLC (Gateway), a personal genomics company and developer of consumer genetic tests that give families insight into their future children.
The company currently focuses on innovation and growth in three key areas: Oncology, Women's Health, and Pharmacogenomics.
Oncology (41.8% of revenues in 2023, up 8.3% from 2022): In oncology, the company offer testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments.
Women's Health (39.8%, up 15.5%): Within Women’s Health, the company provides differentiated genetic insights for women of all ancestries, assessing cancer risk, and offering prenatal testing solutions.
Pharmacogenomics (18.4%, up 8.5%): In Pharmacogenomics, the company provides genetic insights to help physicians understand how genetic alterations impact patient response to anti-depressants and other drugs.
General Information
Myriad Genetics, Inc
322 NORTH 2200 WEST
SALT LAKE CITY, UT 84116
Phone: 801-584-3600
Fax: 801-584-3640
Email: matt.scalo@myriad.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/4/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.02 |
Current Year EPS Consensus Estimate | 0.10 |
Estimated Long-Term EPS Growth Rate | 51.30 |
Exp Earnings Date | 11/4/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 26.93 |
52 Week High | 29.30 |
52 Week Low | 13.82 |
Beta | 1.92 |
20 Day Moving Average | 744,859.44 |
Target Price Consensus | 30.00 |
4 Week | -3.45 |
12 Week | 7.23 |
YTD | 38.72 |
4 Week | -5.26 |
12 Week | 3.04 |
YTD | 15.41 |
Shares Outstanding (millions) | 90.82 |
Market Capitalization (millions) | 2,411.28 |
Short Ratio | NA |
Last Split Date | 3/26/2009 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 276.56 |
Trailing 12 Months | 531.00 |
PEG Ratio | 5.39 |
vs. Previous Year | 52.38% |
vs. Previous Quarter | 28.57% |
vs. Previous Year | 15.26% |
vs. Previous Quarter | 4.60% |
Price/Book | 3.25 |
Price/Cash Flow | NA |
Price / Sales | 3.01 |
6/30/24 | -5.64 |
3/31/24 | -6.77 |
12/31/23 | -8.03 |
6/30/24 | -3.73 |
3/31/24 | -4.37 |
12/31/23 | -5.24 |
6/30/24 | 1.96 |
3/31/24 | 1.99 |
12/31/23 | 2.01 |
6/30/24 | 1.78 |
3/31/24 | 1.82 |
12/31/23 | 1.87 |
6/30/24 | -5.22 |
3/31/24 | -6.48 |
12/31/23 | -8.10 |
6/30/24 | -19.35 |
3/31/24 | -30.30 |
12/31/23 | -34.96 |
6/30/24 | -19.52 |
3/31/24 | -30.42 |
12/31/23 | -34.81 |
6/30/24 | 8.18 |
3/31/24 | 8.40 |
12/31/23 | 9.53 |
6/30/24 | 10.15 |
3/31/24 | 10.26 |
12/31/23 | 10.34 |
6/30/24 | 0.05 |
3/31/24 | 0.05 |
12/31/23 | 0.05 |
6/30/24 | 4.98 |
3/31/24 | 4.85 |
12/31/23 | 4.69 |